;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Aironite: Phase II data

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Aironite (AIR001) Business: Cardiovascular Molecular target: NA Description: Inhaled nebulized sodium nitrite Indication: Treat pulmonary arterial …

    Published on 9/15/2014
  • Basimglurant: Development discontinued

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Basimglurant (RG7090, RO4917523) Business: Neurology Molecular target: Metabotropic glutamate receptor …

    Published on 9/15/2014
  • Benralizumab: Phase IIa data

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Benralizumab (KHK4563, MEDI-563) (formerly BIW-8405) Business: Pulmonary Molecular target: Interleukin-5 (…

    Published on 9/15/2014
  • BioChaperone Lispro U100: Preliminary Phase IIb data

    Adocia S.A. (Euronext:ADOC; Pink:ADOCY), Lyon, France Product: BioChaperone Lispro U100 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Ultra-fast acting formulation of insulin …

    Published on 9/15/2014
  • C16G2: Phase II data

    C3 Jian Inc., Marina del Rey, Calif. Product: C16G2 Business: Dental Molecular target: NA Description: Synthetic peptide targeting Streptococcus mutans derived from specifically targeted antimicrobial peptides (STAMPS) …

    Published on 9/15/2014
  • Cyramza ramucirumab: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab (LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) …

    Published on 9/15/2014
  • DLX105 topical: Phase II data

    Delenex Therapeutics AG, Zurich, Switzerland Product: DLx105 topical Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Topical formulation of an anti-tumor necrosis factor…

    Published on 9/15/2014
  • GNbAC1: Extension study data

    GeNeuro S.A., Geneva, Switzerland Product: GNbAC1 Business: Autoimmune Molecular target: NA Description: Humanized mAb targeting the envelop protein of human endogenous retrovirus type W (HERV-W) Indication: Treat …

    Published on 9/15/2014
  • IdeS: Phase II data

    Hansa Medical AB (SSE:HMED), Lund, Sweden Product: IdeS Business: Transplant Molecular target: NA Description: Streptococcus pyogenes enzyme that degrades IgG antibodies Indication: Prevent renal transplant rejection in…

    Published on 9/15/2014
  • Lyrica pregabalin: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lyrica pregabalin Business: Neurology Molecular target: GABA receptor Description: GABA receptor agonist Indication: Treat painful diabetic peripheral neuropathy (DPN) …

    Published on 9/15/2014
  • MIM-D3: Phase III data

    Mimetogen Pharmaceuticals Inc., Montral, Quebec Product: MIM-D3 Business: Ophthalmic Molecular target: Nerve growth factor (NGF) Description: Small molecule mimetic of nerve growth factor (NGF) Indication: Treat dry eye…

    Published on 9/15/2014
  • Moxifloxacin: Phase III data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Global Alliance for TB Drug Development, New York, N.Y. Product: Moxifloxacin (Actira, Octegra, Avalox) Business: Infectious Molecular target: DNA gyrase; Topoisomerase IV …

    Published on 9/15/2014
  • Prurisol abacavir acetate: Phase I data

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Prurisol abacavir acetate (KM-133) Business: Autoimmune Molecular target: NA Description: Small molecule ester of abacavir, a nucleoside analog reverse …

    Published on 9/15/2014
  • RPC1063: Phase II data

    Receptos Inc. (NASDAQ:RCPT), San Diego, Calif. Product: RPC1063 Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Selective sphingosine-1-phosphate receptor 1 (…

    Published on 9/15/2014
  • Tecemotide: Development discontinued

    Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Merck KGaA (Xetra:MRK), Darmstadt, Germany Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Tecemotide (L-BLP25) (formerly Stimuvax) Business: Cancer …

    Published on 9/15/2014
  • VRC-CHKVLP059-00-VP vaccine: Phase I data

    National Institutes of Health, Bethesda, Md. Product: VRC-CHKVLP059-00-VP vaccine Business: Infectious Molecular target: NA Description: Virus-like particle (VLP) containing the outer structural proteins of the West …

    Published on 9/15/2014
  • Vyvanse: Phase IV data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Vyvanse (Elvanse, Tyvense, Venvanse) lisdexamfetamine dimesylate (S-877489) Business: Neurology Molecular target:…

    Published on 9/15/2014
  • Vyvanse: Phase IV data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Vyvanse (Elvanse, Tyvense, Venvanse) lisdexamfetamine dimesylate (S-877489) Business: Neurology Molecular target:…

    Published on 9/15/2014
  • Aerosolized Alpha-1 antitrypsin: Phase II/III final data

    Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel Pari GmbH, Starnberg, Germany Product: Aerosolized Alpha-1 antitrypsin (AAT) (AAT-IH) Business: Endocrine/Metabolic Molecular target: Alpha 1-antitrypsin (AAT…

    Published on 9/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 9/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 9/8/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 9/8/2014
  • ATL1103: Additional Phase II data

    Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ATL1103 Business: Endocrine/Metabolic Molecular target: Growth hormone receptor Description: …

    Published on 9/8/2014
  • Basal insulin peglispro: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Basal insulin peglispro (LY2605541) Business: Endocrine/Metabolic Molecular target: NA Description: Once-daily basal insulin analog Indication: Treat Type I …

    Published on 9/8/2014
  • Basal insulin peglispro: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Basal insulin peglispro (LY2605541) Business: Endocrine/Metabolic Molecular target: NA Description: Once-daily basal insulin analog Indication: Treat Type I …

    Published on 9/8/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993